DBV Technologies | DBVT - Ebitda



金融业
股票价格
USD
资产
USD 233.72M
现金及等价物
USD 194.17M
流动资产
USD 212.94M
流动负债
USD 58.03M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 168.77M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 727.7M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


Ebitda 更改 日
Acadia Pharmaceuticals USD 20.31M 15.44M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amarin USD 12.54M 28.57M 2025-06
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
DBV Technologies USD -33.48M 5.55M 2025-09
Esperion Therapeutics USD -9.93M 24.99M 2025-09
Galectin Therapeutics USD -7.42M 819K 2021-12
Halozyme Therapeutics USD 219.57M 197.66M 2026-03
Incyte USD 367.97M 46.53M 2026-03
Insmed USD -148.3M 165.88M 2026-03
Ionis Pharmaceuticals USD -200.02M 42.89M 2025-12
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
PTC Therapeutics USD -70.99M 91.62M 2025-12
Sarepta Therapeutics USD -252.2M 84.16M 2025-12
Ultragenyx Pharmaceutical USD -99.43M 57.35M 2025-12
United Therapeutics USD 379.5M 83.4M 2025-12